A Study of MEDI1191 in sequential and concurrent combination with Durvalumab in Subjects with Advanced Solid Tumors

Trial Identifier: D8510C00001
Sponsor: MedImmune, LLC
NCTID:: NCT03946800
Start Date: May 2019
Primary Completion Date: August 2023
Study Completion Date: August 2023
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Spanish Translation

Trial Locations

Country Location
ES Barcelona, ES, 08035
ES Madrid, ES, 28027
ES Pamplona, ES, 31008
US, CA La Jolla, CA, US, 92093
US, CA Los Angeles, CA, US, 90089
US, CA Los Angeles, CA, US, 90025
US, NY Bronx, NY, US, 10461
US, NY New York, NY, US, 10029
US, NY New York, NY, US, 10065
US, RI Providence, RI, US, 02903
US, TX Houston, TX, US, 77030